Скачать или смотреть CRISPR's Lung Cancer Breakthrough

In November 2025, scientists achieved a remarkable breakthrough in cancer treatment using CRISPR technology. Researchers at ChristianaCare's Gene Editing Institute discovered that disabling the NRF2 gene in lung cancer cells could reverse chemotherapy resistance and slow tumor growth. The NRF2 gene normally regulates cellular stress responses, but when overactive due to mutations like the R34G variant, it helps cancer cells resist treatment. What makes this discovery particularly promising is that editing just 20-40% of tumor cells was sufficient to restore chemotherapy sensitivity, making clinical application more feasible. This approach could transform treatment for various resistant cancers beyond just lung cancer, offering new hope for patients facing treatment-resistant tumors through a precision medicine strategy that targets the root cause of resistance.